Abstract To provide a National database, 1,410 unrelated hemophilia A (HA) patients were investigated using screening methods denaturing high-performance liquid chromatography (DHPLC), conformational-sensitive gel electrophoresis (CSGE)] and/or direct sequencing. F8 gene mutations were identified in 877 (81%), 146 (82%), and 133 (89%) families with severe, moderate, or mild HA, respectively. Among the 382 different mutations detected, 217 (57%) have not previously been reported in the F8 Haemophilia A Mutation, Structure, Test and Resource Site (HAMSTeRS) database. Mutations leading to a null allele accounted for 82, 15%, and less than 1% of severe, moderate, or mild HA, respectively. A missense mutation was identified in 16%, 68%, and 81% of severe, moderate, or mild HA, respectively. They included 105 missense mutations (48%), 41 small deletions (19%), 25 splice site mutations (12%), 24 nonsense mutations (11%), 18 insertions (8%), three large deletions (1%), and one deletion plus insertion. Unreported mutations were distributed throughout the F8 gene, as they affected all F8 exons but exon 20. We report a wide spectrum of mutations collected in a large National database. The type of mutation was a strong predictor of the clinical phenotype. This database is expected to considerably improve the genetic counseling and medical care of HA families in Italy.
Introduction
Hemophilia A (HA) is an X-linked bleeding disorder caused by heterogeneous mutations in the Factor 8 (F8) gene. Its incidence is estimated at 1:5,000-10,000 in men (Kazazian et al. 1995) . The F8 gene maps to the distal end of the long arm of X-chromosome (Xq28) and spans 186 kb of genomic DNA. It consists of 26 exons and encodes a mature protein of 2,332 amino acids (Kazazian et al. 1995) . Over the last decades, rapidly increasing numbers of causative gene alterations have been described in different ethnic groups. Actually, more than 900 mutations within the F8 coding and untranslated regions have been identified and listed in the F8 Haemophilia A Mutation, Structure, Test and Resource Site (HAMSTeRS) mutation database (URL: http://europium.csc.mrc.ac.uk) (Gitschier et al. 1984) . These findings further support the concept that HA has a very high mutational heterogeneity and represents a challenge for the provision of genetic services because carrier and prenatal diagnosis cannot be based on the screening of a limited number of common mutations (Kemball-Cook et al. 1998) . The exponential discovery rate of new genomic alterations, leading to HA, as well as the need for comparative studies of different population's mutation frequencies, requires recording their population-wide spectrum in mutation databases. These databases are likely to facilitate genetic consultation of patients' families and can help optimize national DNA diagnostic services also by enhancing awareness among clinicians, patients, and the general public. Finally, mutation analysis of a given population is useful for further understanding structural and functional aspects of the mutant protein and the correlation between genotype and phenotype. Therefore, the Italian Association of Hemophilia Centres (AICE) planned to set up a National database aiming at characterizing the F8 gene mutations to elucidate molecular basis of HA in Italy and to provide insight into protein structure-function relationships, unraveling the correlation (if any) between genotype and clinical phenotype.
In this study, we report phenotypic and genotypic data from 1,410 independent HA families comprising about 82% of Italian HA patients. These data strengthen the relevance for a National Hemophilia Registry that is expected to considerably improve the medical care of HA families in Italy with respect to treatment and genetic counseling.
Materials and methods
The study was carried out according to the Principles of the Declaration of Helsinki; informed consent was obtained from all participants. All patients involved in this study are regularly followed at one of 49 hemophilia treatment centers (see ''Appendix'') spread all over the country and belonging to AICE (URL: http://www.aiceonline.it), an organization founded with the aim of organizing national clinical and research activities in inherited bleeding disorders. Patients were considered to have HA according to the international consensus of the 2001 International Society on Thrombosis and Haemostasis (ISTH) Factor VIII and Factor IX Subcommittee (White et al. 2001) . All known HA patients are registered and followed at one of these centers. For each patient, clinical and laboratory data (including FVIII clotting activity and inhibitor) are recorded.
DNA collection
A blood sample (5-10 mL) was collected in ethylenediaminetetraacetate (EDTA) or sodium citrate from each patient and stored at -20°C until sent to one of the nine laboratories that performed the genetic analysis. Isolation of DNA from leukocytes was carried out according to standard procedures (Miller et al. 1988) .
PCR detection of the introns 1 and 22 inversion
Intron 1 inversions were detected by polymerase chain reaction (PCR), as reported earlier (Bagnall et al. 2002) . Long PCR for detecting the intron 22 inversion was performed as previously described (Liu et al. 1998 ).
Amplification of the F8 gene PCR was carried out according to standard procedures (D'Andrea et al. 2002) . A total of 14 kb of the F8 gene, including the entire coding sequence, exon-intron junctions, and part of the 5 0 and 3 0 untranslated regions, were amplified by PCR. Most of the primers and amplification conditions have been previously reported; primer sequences, annealing temperatures, and the size of PCR fragments are available on request.
Mutation detection screening
Mutational analysis was performed through all of the coding exons and the exon/intron boundaries of the F8 gene using denaturing high-performance liquid chromatography (DHPLC) analysis in four of the nine laboratories (Firenze, Genova, Parma, and Vicenza), whereas another one (Castelfranco Veneto) used conformational-sensitive gel electrophoresis (CSGE). The success rate ranged from 80% to 95%. All amplification products that showed an abnormal pattern were then analyzed by direct sequencing. The remaining four laboratories (Foggia, Milano, Napoli, and Padova) did not employ any screening method, and samples were subjected to direct gene sequencing.
DNA sequencing
Amplified DNA fragments were purified and subjected to direct cycle sequence analysis using the Taq dye-deoxy terminator method and an ABI PRISM 3100 genetic Analyzer sequencer (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. All the nucleotide changes identified were confirmed by repeating the PCR and sequencing reactions. To address whether new mutations identified would be a polymorphism, 100 control subjects from the same ethnic background were investigated. Mutation nomenclature was according to the F8 HAMSTeRS mutation database (URL: http://europium. csc.mrc.ac.uk).
Splice-site prediction
Missense mutations and mutations at or near the splice junction consensus sequences were analyzed by the Splice Site Prediction program (http://www.fruitfly.org/seq_tools/ splice.html) to predict the changes in RNA splicing.
Results
F8 gene mutations were identified in 1,156 out of 1,410 unrelated families with a history of HA, representing a mutation detection rate of 82%. Among these unrelated families, at least one causal F8 mutation was identified in 877 (81%), 146 (82%), and 133 (89%) families with severe, moderate, or mild HA, respectively. Among severe HA patients, in addition to intron 22 and 1 inversion, 272 different mutations were recorded, including 100 missense mutations, 63 small deletions, 47 nonsense mutations, 25 splice-site mutations, 24 small insertions, 11 large deletions (seven spanning more than one domain), and two involving different mechanisms (deletion + insertion; missense/splicing) (Fig. 1a) . In patients presenting with moderate HA, 83 different mutations were recorded, including 59 missense mutations, six splice-site mutations, six small deletions, six nonsense mutations, five small insertion, and one involving a different mechanism (duplication of exon 13) (Acquila et al. 2004) (Fig. 1b) .
Finally, in mild HA patients, 57 different mutations were found, including 50 missense mutations, five splice-site mutations, one small deletion, and duplication of exon 13 (Acquila et al. 2004) (Fig. 1c) . Overall, mutations that are likely to give rise to a null allele (inversions of an intron, deletions, insertions, and nonsense mutations) accounted for 82% of severe, 15% of moderate, and less than 1% of mild HA families. On the other hand, a missense mutation was identified in 16% of severe, 68% of moderate, and 81% of mild HA families. Mutations predicted to affect F8 mRNA splicing occurred in 4% of severe, 16% of moderate, and 5% of mild HA families, suggesting that for most of splice-site mutations, by escaping aberrant splicing, a rescue of low levels of normal transcripts may take place. Among the 384 different mutations detected, 217 (57%) have not previously been reported in the F8 HAMSTeRS mutation database. They include 105 missense mutations (48%), 41 small deletions (19%), 25 splice-site mutations (12%), 24 nonsense mutations (11%), 18 insertions (8%), three large deletions (1%), and one deletion + insertion (Table 1) . Unreported mutations were distributed throughout the F8 gene, as they affected all F8 exons but exon 20.
Exon 14 accounts for approximately 43% (3,106 out of 7,227 bp) of the coding region. Unreported mutations were found more frequently in exon 14, with 47 of 233 different mutations (21%) occurring in this portion of the F8 gene. Novel mutations identified consisted mainly in premature terminal codon-causing mutations with 19 small deletions (41%), 11 insertions (23%), 11 nonsense mutations (23%), two splice-site mutations (4%), and only four missense mutations (9%).
Discussion
We report herein the largest series of F8 analysis in HA patients issued in Italy. The vast majority of Italian families with HA, especially those with the severe cases, were included in this study, and it may be considered to be representative for the purpose of a population-based study of mutational heterogeneity. Actually, we were able to find 384 different mutations among 1,410 unrelated families. In accordance with previous data, more than 25% of these unrelated families of our cohort presented a novel mutation (Ljung and Sjorin 1999; Habart et al. 2003; Oldenburg and Pavlova 2006) . This reflects the high degree of heterogeneity of the F8-affecting mutations outside inversion of introns 22 and 1. Our study confirms the well-known correlation between the type of mutation and the severity of HA. The type of mutations found was in agreement with results reported in other settings (Oldenburg and Pavlova 2006; Fernández-López et al. 2005; Jayandharan et al. 2005; Deszo et al. 2006) . As would be expected, most severe HA patients carry a molecular defect leading to a null allele (large deletion, inversion, nonsense, and insertion/deletion mutations), whereas missense mutations have been found in the majority of moderate (68%) and mild HA patients (81%). Likewise, most mutations predicted to affect F8 mRNA splicing occurred in moderate or mild HA families, suggesting that low levels of normal transcripts may escape aberrant splicing. To improve genetic counseling and medical care of HA families, mutations identified in this work will be available at the HAMSTeRS mutation database.
Exon 14 represents about one half of the coding region and encodes for the F8 B domain, a region lacking in procoagulant activity that is spliced out from the mature protein. This finding explains the occurrence of very few missense mutations in the central portion of exon 14 in our series and in other settings (see: HAMSTeRS mutation database).
In conclusion, we report a large National database in which a wide spectrum of new mutations has been collected. The type of mutation was a strong predictor of the clinical phenotype. This database will be of great value for genetic counseling in HA and is expected to considerably improve the medical care of HA families in Italy. 
